Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Seizures D012640 87 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Atherosclerosis D050197 85 associated lipids
Stomach Ulcer D013276 75 associated lipids
Hyperlipidemias D006949 73 associated lipids
Carcinoma, Non-Small-Cell Lung D002289 72 associated lipids
Coronary Disease D003327 70 associated lipids
Colitis D003092 69 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Reperfusion Injury D015427 65 associated lipids
Pain D010146 64 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Weight Loss D015431 56 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Asthma D001249 52 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Thrombosis D013927 49 associated lipids
Fatty Liver D005234 48 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Hyperalgesia D006930 42 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Arthritis D001168 41 associated lipids
Hypotension D007022 41 associated lipids
Diabetic Nephropathies D003928 39 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Zellweger Syndrome D015211 39 associated lipids
Lung Diseases D008171 37 associated lipids
Heart Failure D006333 36 associated lipids
Liver Cirrhosis, Experimental D008106 36 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Kambara T et al. Propofol suppresses prostaglandin E(2) production in human peripheral monocytes. 2009 Immunopharmacol Immunotoxicol pmid:19951072
Hu Y et al. Chinese herbal medicinal ingredients inhibit secretion of IL-6, IL-8, E-selectin and TXB2 in LPS-induced rat intestinal microvascular endothelial cells. 2009 Immunopharmacol Immunotoxicol pmid:19874221
Li M et al. Effects of pathological flow on pulmonary artery endothelial production of vasoactive mediators and growth factors. 2009 J. Vasc. Res. pmid:19571576
McClelland S et al. Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse. 2009 Atherosclerosis pmid:18514659
Coates AM et al. Regular consumption of n-3 fatty acid-enriched pork modifies cardiovascular risk factors. 2009 Br. J. Nutr. pmid:18590592
Xu Y et al. Urocortin promotes the development of vasculitis in a rat model of thromboangiitis obliterans via corticotrophin-releasing factor type 1 receptors. 2009 Br. J. Pharmacol. pmid:19572944
Zhao L et al. Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor. 2009 Br. J. Pharmacol. pmid:19220291
Shah KB et al. The cardioprotective effects of fish oil during pressure overload are blocked by high fat intake: role of cardiac phospholipid remodeling. 2009 Hypertension pmid:19597033
Ulbrich SE et al. Quantitative characterization of prostaglandins in the uterus of early pregnant cattle. 2009 Reproduction pmid:19470711
Santilli F et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". 2009 J. Am. Coll. Cardiol. pmid:19232899
Lev EI Aspirin resistance transient laboratory finding or important clinical entity? 2009 J. Am. Coll. Cardiol. pmid:19232900
Bernoud-Hubac N et al. Low concentrations of reactive gamma-ketoaldehydes prime thromboxane-dependent human platelet aggregation via p38-MAPK activation. 2009 Biochim. Biophys. Acta pmid:19233311
Giraudel JM et al. Differential inhibition of cyclooxygenase isoenzymes in the cat by the NSAID robenacoxib. 2009 J. Vet. Pharmacol. Ther. pmid:19161453
Jespersen B et al. Differential effects of immunosuppressive drugs on COX-2 activity in vitro and in kidney transplant patients in vivo. 2009 Nephrol. Dial. Transplant. pmid:19193738
Chen SS et al. Elevated plasma prostaglandins and acetylated histone in monocytes in Type 1 diabetes patients. 2009 Diabet. Med. pmid:19236624
Kanazawa S et al. Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer. 2009 Platelets pmid:19172526
Calapai G et al. Cardiovascular biomarkers in groups of established smokers after a decade of smoking. 2009 Basic Clin. Pharmacol. Toxicol. pmid:19175368
Kapetanovic IM et al. Comparison of pharmacokinetic and pharmacodynamic profiles of aspirin following oral gavage and diet dosing in rats. 2009 Chem. Biol. Interact. pmid:18992230
Seta F et al. Renal and cardiovascular characterization of COX-2 knockdown mice. 2009 Am. J. Physiol. Regul. Integr. Comp. Physiol. pmid:19357295
Pettinella C et al. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin. 2009 Thromb. Haemost. pmid:19350112
Basselin M et al. Imaging elevated brain arachidonic acid signaling in unanesthetized serotonin transporter (5-HTT)-deficient mice. 2009 Neuropsychopharmacology pmid:19145225
Dołegowska B et al. Platelets arachidonic acid metabolism in patients with essential hypertension. 2009 Platelets pmid:19440924
Ahmad M et al. Prolonged opportunity for neuroprotection in experimental stroke with selective blockade of cyclooxygenase-2 activity. 2009 Brain Res. pmid:19446533
Mayer K et al. Acute lung injury is reduced in fat-1 mice endogenously synthesizing n-3 fatty acids. 2009 Am. J. Respir. Crit. Care Med. pmid:19136374
Schuijt MP et al. The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. 2009 Br. J. Pharmacol. pmid:19466986
Eriksson AC et al. Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study. 2009 J Transl Med pmid:19508722
Cattaneo M Letter by cattaneo regarding article, "incomplete inhibition of thromboxane biosynthesis by acetylsalicylic Acid: determinants and effect on cardiovascular risk". 2009 Circulation pmid:19546394
Schiff M et al. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. 2009 Curr Med Res Opin pmid:19678751
Cook VL et al. Effect of firocoxib or flunixin meglumine on recovery of ischemic-injured equine jejunum. 2009 Am. J. Vet. Res. pmid:19645580
Blais N et al. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). 2009 Thromb. Haemost. pmid:19652893
Zhang X et al. Effect of baicalin on inflammatory mediator levels and microcirculation disturbance in rats with severe acute pancreatitis. 2009 Pancreas pmid:19657312
Liu FC et al. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase. 2009 Biochem. Pharmacol. pmid:19426675
Peng CY et al. Dietary soy protein selectively reduces renal prostanoids and cyclooxygenases in polycystic kidney disease. 2009 Exp. Biol. Med. (Maywood) pmid:19429858
Csányi G et al. Effects of 3-aminopyridine-induced seizures on platelet eicosanoid synthesis. 2008 May-Jun Pharmacol Rep pmid:18622059
Lessa A et al. The effect of pentoxifylline on the pulmonary response to high tidal volume ventilation in rats. 2008 Pulm Pharmacol Ther pmid:17251044
Dobaczewski M et al. Targeting the urine and plasma determinants of thromboxane A2 metabolism in detection of aspirin effectiveness. 2008 Blood Coagul. Fibrinolysis pmid:18600093
Rossoni G et al. Combined simvastatin-manidipine protect against ischemia-reperfusion injury in isolated hearts from normocholesterolemic rats. 2008 Eur. J. Pharmacol. pmid:18442813
Yan Q et al. Female ROMK null mice manifest more severe Bartter II phenotype on renal function and higher PGE2 production. 2008 Am. J. Physiol. Regul. Integr. Comp. Physiol. pmid:18579648
Gao L et al. [Effects of supplementing qi and activating blood circulation method on platelet aggregation rate, adhesion rate and thromboxane B2 level in patients with stable angina pectoris and intolerable to aspirin]. 2008 Zhongguo Zhong Xi Yi Jie He Za Zhi pmid:18543479
Patrignani P et al. Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. 2008 Pharmacogenet. Genomics pmid:18551041
Francois H et al. A role for the thromboxane receptor in L-NAME hypertension. 2008 Am. J. Physiol. Renal Physiol. pmid:18684890
Guthikonda S et al. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. 2008 Thromb. Haemost. pmid:18612542
Elander N et al. Genetic deletion of mPGES-1 accelerates intestinal tumorigenesis in APC(Min/+) mice. 2008 Biochem. Biophys. Res. Commun. pmid:18485889
Park JW et al. 15,16-dihydrotanshinone I, a major component from Salvia miltiorrhiza Bunge (Dansham), inhibits rabbit platelet aggregation by suppressing intracellular calcium mobilization. 2008 Arch. Pharm. Res. pmid:18277607
Schwartz JI et al. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. 2008 J Clin Pharmacol pmid:18434566
Cui J et al. Cyclooxygenase inhibition attenuates sympathetic responses to muscle stretch in humans. 2008 Am. J. Physiol. Heart Circ. Physiol. pmid:18441194
Karon BS et al. Aspirin responsiveness in healthy volunteers measured with multiple assay platforms. 2008 Clin. Chem. pmid:18420732
Hinz B et al. Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. 2008 Int J Clin Pharmacol Ther pmid:18397691
Bruce EC et al. Platelet thromboxane A2 secretion in patients with major depression responsive to electroconvulsive therapy. 2008 Psychosom Med pmid:18378867
Wooten JG et al. Cyclooxygenase expression and prostanoid production in pyloric and duodenal mucosae in dogs after administration of nonsteroidal anti-inflammatory drugs. 2008 Am. J. Vet. Res. pmid:18380576